lung and/or heart failure
Conditions
Brief summary
To comprehensively compare the efficacy and safety of anticoagulation therapy in patients on ECMO support with argatroban, enoxaparin and in the combined population of patients with argatroban or enoxaparin
Detailed description
To determine the relationship between argatroban concentration and the incidence of bleeding and thrombotic complications and the consumption of blood derivatives and transfusion products, To determine the relationship between the dose or concentration of anticoagulant and laboratory parameters for monitoring anticoagulation, To determine the relationship between laboratory parameters and bleeding and thrombotic complications
Interventions
DRUGArgatra Multidose 100 mg/ml Konzentrat zur Herstellung einer Infusionslösung
DRUGCLEXANE 10 000 IU (100 mg)/1 ml injekční roztok v předplněné injekční stříkačce
Sponsors
Fakultni Nemocnice Ostrava
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To comprehensively compare the efficacy and safety of anticoagulation therapy in patients on ECMO support with argatroban, enoxaparin and in the combined population of patients with argatroban or enoxaparin | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the relationship between argatroban concentration and the incidence of bleeding and thrombotic complications and the consumption of blood derivatives and transfusion products, To determine the relationship between the dose or concentration of anticoagulant and laboratory parameters for monitoring anticoagulation, To determine the relationship between laboratory parameters and bleeding and thrombotic complications | — |
Outcome results
None listed